Meeting
2020 ASCO Virtual Scientific Program
Real-world (RW) outcomes for advanced non-small cell lung cancer (aNSCLC) patients (pts) with EGFR exon 19 deletions (x19del) stratified by deletion size.
Authors
Sai-Hong Ignatius Ou
Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA
Sai-Hong Ignatius Ou , Russell Madison , Tamara Snow , Jeremy Snider , Margaret Elizabeth McCusker , Gaurav Singal , Brian Michael Alexander , Jeffrey Venstrom , Emily Castellanos , Alexa Betzig Schrock
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9591)
DOI
10.1200/JCO.2020.38.15_suppl.9591
Abstract #
9591
Poster Bd #
357
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Quality Care Symposium
Stepwise prolongation of overall survival from first- to third-generation EGFR-tyrosine kinase inhibitors in non-small cell lung cancer and the prognostic impact of concomitant antacids.
First Author: Kiyoaki Uryu
Poster
2021 ASCO Quality Care Symposium
Real-world treatment patterns of metastatic non-small cell lung cancer (mNSCLC) patients receiving epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).
First Author: Rahul Shenolikar
Poster
2021 ASCO Annual Meeting
Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG).
First Author: Satoru Miura
Poster
2021 ASCO Annual Meeting
Outcomes of first-generation versus third-generation epidermal growth factor receptor (EGFR) inhibitors in non-small cell lung cancer with brain metastases (NSCLCBM).
First Author: Vineeth Tatineni